1. Home
  2. WVE vs APOG Comparison

WVE vs APOG Comparison

Compare WVE & APOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WVE
  • APOG
  • Stock Information
  • Founded
  • WVE 2012
  • APOG 1949
  • Country
  • WVE Singapore
  • APOG United States
  • Employees
  • WVE N/A
  • APOG 4400
  • Industry
  • WVE Biotechnology: Pharmaceutical Preparations
  • APOG Auto Parts:O.E.M.
  • Sector
  • WVE Health Care
  • APOG Consumer Discretionary
  • Exchange
  • WVE Nasdaq
  • APOG Nasdaq
  • Market Cap
  • WVE 2.1B
  • APOG 1.7B
  • IPO Year
  • WVE 2015
  • APOG N/A
  • Fundamental
  • Price
  • WVE $13.70
  • APOG $73.87
  • Analyst Decision
  • WVE Strong Buy
  • APOG Hold
  • Analyst Count
  • WVE 10
  • APOG 1
  • Target Price
  • WVE $21.60
  • APOG $75.00
  • AVG Volume (30 Days)
  • WVE 947.4K
  • APOG 133.3K
  • Earning Date
  • WVE 11-12-2024
  • APOG 01-07-2025
  • Dividend Yield
  • WVE N/A
  • APOG 1.34%
  • EPS Growth
  • WVE N/A
  • APOG 4.28
  • EPS
  • WVE N/A
  • APOG 4.74
  • Revenue
  • WVE $53,610,000.00
  • APOG $1,375,510,000.00
  • Revenue This Year
  • WVE N/A
  • APOG N/A
  • Revenue Next Year
  • WVE $48.58
  • APOG $4.80
  • P/E Ratio
  • WVE N/A
  • APOG $15.77
  • Revenue Growth
  • WVE N/A
  • APOG N/A
  • 52 Week Low
  • WVE $3.50
  • APOG $50.78
  • 52 Week High
  • WVE $16.74
  • APOG $87.93
  • Technical
  • Relative Strength Index (RSI)
  • WVE 48.19
  • APOG 36.27
  • Support Level
  • WVE $13.11
  • APOG $74.65
  • Resistance Level
  • WVE $15.54
  • APOG $81.50
  • Average True Range (ATR)
  • WVE 0.89
  • APOG 1.88
  • MACD
  • WVE -0.19
  • APOG -1.06
  • Stochastic Oscillator
  • WVE 27.52
  • APOG 14.19

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About APOG Apogee Enterprises Inc.

Apogee Enterprises Inc provider of architectural products and services for enclosing buildings, and high-performance glass and acrylic products used in applications for preservation, protection, and enhanced viewing. Its segments are Architectural Framing Systems; Architectural Glass; Architectural Services and Large-Scale Optical Technologies (LSO). It generates maximum revenue from the Architectural Framing Systems segment. The Architectural Framing Systems segment designs, engineers, fabricates, and finishes the aluminum frames used in customized aluminum and glass windows, curtainwall, storefront, and entrance systems comprising the outside skin and entrances of commercial, institutional, and others. Geographically, it derives a majority of its revenue from the United States.

Share on Social Networks: